Myonex ApS: Financial statements 2022
CVR: 39905094
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Myonex ApS (CVR 39905094) has filed annual accounts for 2022. In 2022, the company reported a gross profit of EUR 11,411,359 and a net result of EUR 8,755,907 compared with EUR 6,237,759,000 the year before. That is a decrease of 99.9% compared with the year before. Equity in the 2022 report amounted to EUR 14,871,007. The solvency ratio was 87.2%.
- Gross Profit
- EUR 11,411,359
- Profit/Loss
- EUR 8,755,907
- Equity
- EUR 14,871,007
- Total Assets
- EUR 17,050,375
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 11.4M EUR | 8.8M EUR | 14.9M EUR | - |
| 2021 | - | 8.1B EUR | 6.2B EUR | 6.1B EUR | - |
| 2020 | - | -104K EUR | -105K EUR | -179K EUR | - |
Official annual report
Keep an eye on Myonex ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of October 17, 2022, James Whitfield Lovett is registered as director of Myonex ApS.
As of October 17, 2022, Gregory Thomas Lavin is registered as director of Myonex ApS.
Myonex ApS has published its annual report for 2021. Gross profit came to DKK 8,057,814,000, and the net result was DKK 6,237,759,000.
As of January 5, 2022, AIDER Godkendt Revisionsaktieselskab has been appointed auditor of Myonex ApS.
About Myonex ApS
Myonex ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Myoderm ApS. The management consists of Gregory Thomas Lavin and Michael Allen Cohen. The company is owned by Myonex, LLC. In 2025, the company reported a gross profit of EUR 1,009,020 and a net result of EUR 580,466 compared with EUR 2,155,499 the year before. Equity in the 2025 report amounted to EUR 19,516,469.